A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION S (Q59249401)

From Wikidata

Jump to navigation Jump to search

article

Language	Label	Description	Also known as
English	A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION S	article

Statements

scholarly article

0 references

A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION S (English)

0 references

1 reference

based on heuristic

inferred from title

randomized controlled trial

1 reference

based on heuristic

inferred from title

lamivudine/zidovudine

1 reference

based on heuristic

inferred from title

author name string

Princy N Kumar

1

0 references

Patricia Salvato

2

0 references

Anthony LaMarca

3

0 references

Edwin DeJesus

4

0 references

Parul Patel

5

0 references

Daniel McClernon

6

0 references

Allison Florance

7

0 references

Mark S Shaefer

8

0 references

language of work or name

0 references

publication date

9 April 2009

0 references

AIDS Research and Therapy

0 references

6

0 references

1

0 references

3

0 references

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19358725

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19358725

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/19358725

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel

1 reference

https://pubmed.ncbi.nlm.nih.gov/19358725

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the

1 reference

https://pubmed.ncbi.nlm.nih.gov/19358725

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/19358725

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

https://pubmed.ncbi.nlm.nih.gov/19358725

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).

1 reference

https://pubmed.ncbi.nlm.nih.gov/19358725

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/19358725

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19358725

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1742-6405-6-3

0 references

Dimensions Publication ID

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q59249401&oldid=2215216053"